核受体FXR激活对宫颈癌CaSki细胞增殖的抑制效应及其作用机制

doi:10.3969/j.issn.1004-616x.2021.04.011

Abstract

Abstract: OBJECTIVE: To investigate inhibitory effects and the mechanisms of farnesoid X receptor (FXR) on proliferation of a cervical cancer cell line,CaSki. METHODS: FXR was activated by the FXR agonist GW4064 and DMSO was set as the control group at the same time. After treatment with 10 μmol/L GW4064 for 24 and 48 h,the mRNA and protein levels of FXR were detected by fluorescence quantitative PCR and Western blot,respectively. Proliferations of CaSki were detected by using methylthiazolyldiphenyl-tetrazolium bromide (MTT) assay after FXR activation. Cell apoptosis of CaSki was detected by flow cytometry. Western blot was used to detect protein levels of p53. RESULTS: Compared with the control group,expression levels of FXR mRNA and protein in the GW4064 treatment group were increased,cell proliferation rates were decreased,apoptosis rates were increased,and expression levels of p53 protein were increased (all P<0.05). CONCLUSION: Activation of FXR inhibited proliferation of CaSki through promoting cell apoptosis which might be related to increased expression of p53.

Key words: farnesoid X receptor, CaSki, cell proliferation, apoptosis, p53

CLC Number:

R737.33

HUANG Xiaohua, NIU Yongdong, SHI Ganggang. Inhibitory effects and mechanisms of nuclear receptor FXR activation in cervical cancer cell line CaSki[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(4): 302-306.

References

[1] JEMAL A, BRAY F, CENTER M M, et al. Global cancer statistics[J]. CA:A Cancer J Clin, 2011, 61(2):69-90.
[2] DU P L, WU K S, FANG J Y, et al. Cervical cancer mortality trends in China, 1991-2013, and predictions for the future[J]. Asian Pac J Cancer Prev, 2015, 16(15):6391-6396.
[3] YANG X, LU L. Expression of HPV-16 E6 protein and p53 inactivation increases the uterine cervical cancer invasion[J]. Drug Res (Stuttg), 2015, 65(2):70-73.
[4] DESHPANDE R, MANSARA P, KAUL-GHANEKAR R. Alpha-linolenic acid regulates Cox2/VEGF/MAP kinase pathway and decreases the expression of HPV oncoproteins E6/E7 through restoration of p53 and Rb expression in human cervical cancer cell lines[J]. Tumour Biol, 2016, 37(3):3295-3305.
[5] SEOL W, CHOI H S, MOORE D D. Isolation of proteins that interact specifically with the retinoid X receptor:two novel orphan receptors[J]. Mol Endocrinol, 1995, 9(1):72-85.
[6] FORMAN B M, GOODE E, CHEN J, et al. Identification of a nuclear receptor that is activated by farnesol metabolites[J]. Cell, 1995, 81(5):687-693.
[7] DING L, YANG L, WANG Z, et al. Bile acid nuclear receptor FXR and digestive system diseases[J]. Acta Pharm Sin B, 2015, 5(2):135-144.
[8] ZHU J B, XU S, LI J, et al. Farnesoid X receptor agonist obeticholic acid inhibits renal inflammation and oxidative stress during lipopolysaccharide-induced acute kidney injury[J]. Eur J Pharmacol, 2018, 838:60-68.
[9] HUANG H, XU Y, ZHU J, et al. Recent advances in non-steroidal FXR antagonists development for therapeutic applications[J]. Curr Top Med Chem, 2014, 14(19):2175-2187.
[10] ANAYA-HERNáNDEZ A, MéNDEZ-TEPEPA M, HERNáNDEZ-ARAGóN L G, et al. Farnesoid X receptor immunolocalization in reproductive tissues of adult female rabbits[J]. Acta Histochem, 2014, 116(6):1068-1074.
[11] LI X L, WANG Z M, KLAUNIG J E. Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease[J]. Toxicology, 2018, 410:199-213.
[12] YE L S, JIANG Y, ZUO X X. Farnesoid-X-receptor expression in monocrotaline-induced pulmonary arterial hypertension and right heart failure[J]. Biochem Biophys Res Commun, 2015, 467(1):164-170.
[13] XU X, XU X, LIU P, et al. Structural basis for small molecule NDB (N-benzyl-N-(3-(tert-butyl)-4-hydroxyphenyl)-2, 6-dichloro-4-(dimethylamino) benzamide) as a selective antagonist of farnesoid X receptor α (FXRα) in stabilizing the homodimerization of the receptor[J]. J Biol Chem, 2015, 290(32):19888-19899.
[14] LIU X J, ZHANG X W, JI L L, et al. Farnesoid X receptor associates with β-catenin and inhibits its activity in hepatocellular carcinoma[J]. Oncotarget, 2015, 6(6):4226-4238.
[15] HUANG X F, ZHAO W Y, HUANG W D. FXR and liver carcinogenesis[J]. Acta Pharmacol Sin, 2015, 36(1):37-43.
[16] GIAGINIS C, KOUTSOUNAS I, ALEXANDROU P, et al. Elevated Farnesoid X Receptor (FXR) and Retinoid X Receptors (RXRs) expression is associated with less tumor aggressiveness and favourable prognosis in patients with pancreatic adenocarcinoma[J]. Neoplasma, 2015, 62(2):332-341.
[17] DUAN J H, FANG L. microRNA-92 promotes gastric cancer cell proliferation and invasion through targeting FXR[J]. Tumour Biol, 2014, 35(11):11013-11019.
[18] DAI J Q, WANG H X, SHI Y H, et al. Impact of bile acids on the growth of human cholangiocarcinoma via FXR[J]. J Hematol Oncol, 2011, 4:41.
[19] NIU Y D, WANG Z L, HUANG H H, et al. Activated pregnane X receptor inhibits cervical cancer cell proliferation and tumorigenicity by inducing G2/M cell-cycle arrest[J]. Cancer Lett, 2014, 347(1):88-97.
[20] JUŘICA J, DOVRTěLOVá G, NOSKOVá K, et al. Bile acids, nuclear receptors and cytochrome P450[J]. Physiol Res, 2016, 65(Sup 4):S427-S440.
[21] JUNG D, MANGELSDORF D J, MEYER U A. Pregnane X receptor is a target of farnesoid X receptor[J]. J Biol Chem, 2006, 281(28):19081-19091.
[22] ALASMAEL N, MOHAN R, MEIRA L B, et al. Activation of the farnesoid X-receptor in breast cancer cell lines results in cytotoxicity but not increased migration potential[J]. Cancer Lett, 2016, 370(2):250-259.
[23] CATALANO S, PANZA S, MALIVINDI R, et al. Inhibition of leydig tumor growth by farnesoid X receptor activation:The in vitro and in vivo basis for a novel therapeutic strategy[J]. Int J Cancer, 2013, 132(10):2237-2247.
[24] BARRASA J I, SANTIAGO-GóMEZ A, OLMO N, et al. Resistance to butyrate impairs bile acid-induced apoptosis in human colon adenocarcinoma cells via up-regulation of Bcl-2 and inactivation of Bax[J]. Biochim Biophys Acta, 2012, 1823(12):2201-2209.
[25] IM E O, CHOI Y H, PAIK K J, et al. Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells[J]. Cancer Lett, 2001, 163(1):83-93.
[26] AUBREY B J, KELLY G L, JANIC A, et al. How does p53 induce apoptosis and how does this relate to p53-mediated tumour suppression?[J]. Cell Death Differ, 2018, 25(1):104-113.
[27] INGARAMO M C, SáNCHEZ J A, DEKANTY A. Regulation and function of p53:a perspective from Drosophila studies[J]. Mech Dev, 2018, 154:82-90.
[28] GUHA G, LU W L, LI S, et al. Novel pactamycin analogs induce p53 dependent cell-cycle arrest at S-phase in human head and neck squamous cell carcinoma (HNSCC) cells[J]. PLoS One, 2015, 10(5):e0125322.
[29] YADAV V, SULTANA S, YADAV J, et al. Gatifloxacin induces S and G2-phase cell cycle arrest in pancreatic cancer cells via p21/p27/p53[J]. PLoS One, 2012, 7(10):e47796.
[30] JANIC A, VALENTE L J, WAKEFIELD M J, et al. DNA repair processes are critical mediators of p53-dependent tumor suppression[J]. Nat Med, 2018, 24(7):947-953.
[31] KONG B, ZHU Y, LI G D, et al. Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis[J]. Am J Physiol Gastrointest Liver Physiol, 2016, 310(5):G295-G302.

Inhibitory effects and mechanisms of nuclear receptor FXR activation in cervical cancer cell line CaSki

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHAO Yan, SUN Zhenxiao. Metformin inhibitd proliferation and migration of human breast cancer cell in vitro [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2022, 34(1): 35-39.
[2]	LI Boru, QIN Shuangjian, GUAN Lan, LI Runbing, CAI Ying, PU Jiening, ZENG Ming, XIAO Fang, XU Xinyun. Effects of PM_2.5 on oxidative damage and apoptosis in HK-2 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(5): 360-364.
[3]	WANG Xikai, MENG Qinghe, GAO Yanlu. miR-223-3p negatively regulated ECT2 to induce apoptosis in non-small cell lung cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 187-192.
[4]	ZHENG Junwen, CHANG Chen, HAO Jiajie, CAI Yan, WANG Mingrong, ZHANG Yu. Investigation on expression and function of NEDD4 in esophageal squamous cell carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(3): 203-207,224.
[5]	ZHANG Na, FAN Zhilu, YANG Liyan, CHANG Chen, CAI Yan, HAO Jiajie, WANG Mingrong. Clinical significance of decreased SERPINB5 expression in esophageal squamous cell carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 101-109.
[6]	LI Boru, QIN Shuangjian, LI Runbing, CAI Ying, ZHENG Kai, ZENG Ming, XIAO Fang, XU Xinyun. Effects of p38MAPK gene on PM_2.5-induced expression of oncogenes and apoptosis genes in HK-2 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(2): 129-135,142.
[7]	MA Shunpeng, WANG Quankai, WANG Miao, SONG Jiayang, WUHAN Baolier, XIE Guangyun, XU Jianning. Long non-coding RNA regulates apoptosis during glycidyl methacrylate-induced malignant transformation of 16HBE cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 1-5,31.
[8]	LI Boru, QIN Shuangjian, LI Runbing, CAI Ying, ZHENG Kai, WANG Bingyu, ZENG Ming, XIAO Fang, XU Xinyun. Effects of PM_2.5 exposure on expression of oncogenes and apoptosis genes in human renal epithelial cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 6-11.
[9]	HUANG Lili, ZHANG Mengyun, LIU Keliang, PANG Dingguo, LIU Lida, XU Peiyu. Hepatotoxicity of 2,4-dichlorophenoxyacetic acid in young SD rats [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 22-27.
[10]	CUI Zhaoyang, LI Suna, JIANG Xuqian, WANG Yidan, HOU Liying. Activation of the TRAIL death receptor by apigenin for induction of apoptosis in the gastric cancer SGC-7901 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 32-36.
[11]	WANG Yaokun, CHEN Juexiao, ZHANG Mingyuan, SHAO Changli, YANG Yu, SHANG Yu. Database analysis of genome variations and targeted drug screening of anaplastic thyroid cancers [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2021, 33(1): 53-57.
[12]	LAN Li, CHEN Haili, XU Lei. Mechanism of RBMS3-S3 on the proliferation, apoptosis and invasion of cervical cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 438-443.
[13]	LIU Peng, BAI Yixiao. Effect of miR-29a on proliferation and migration of human gastric cancer cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(6): 452-456,463.
[14]	YANG Xingxiao, ZHANG Xueyuan, ZOU Naiyi, SHAN Bao'en, MA Ming, ZHU Shuchai. Effect of HMGB1 silencing by siRNA on radiosensitivity of esophageal carcinoma KYSE30 cells [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 269-274.
[15]	QIN Shuangjian, LI Boru, CAI Ying, ZHENG Kai, WANG Bingyu, LI Runbing, XIAO Fang, ZENG Ming, XU Xinyun. PM_2.5 exposure on expression of oncogenes and apoptosis genes in hepatocytes [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2020, 32(4): 281-285.